Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/29/2023 - 09:30 AM EST

SALT LAKE CITY, Nov. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Piper Sandler 35^th Annual Healthcare Conference in New York City, New York on November 30, 2023.

The presentation will be conducted by Co-Diagnostics CEO Dwight Egan at 12:10 PM EST and will include a discussion of Company progress on its forthcoming Co-Dx™ at-home and point-of-care PCR platform*.

The Company will also be participating in one-on-one meetings with institutional investors, which can be arranged via representatives of Piper Sandler.

*The Co-Dx PCR at-home and point-of-care platform (including the PCR Home™, PCR Pro™, mobile app, and all associated test kits) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-piper-sandler-35th-annual-healthcare-conference-in-new-york-city-on-november-30-2023-302000365.html